Citations

Clear

7551 citation(s) found for "Ho, Matthew".

Prior bariatric surgery may decrease the rate of re-operation and revision following total hip arthroplasty
Martin, J. Ryan , Abdel, M., Lewallen, David G. , Taunton, Michael J. , Watts, Chad D. , Houdek, Matthew T. , Taunton, Michael J

Mayo Clinic

The Bone & Joint Journal | September 1, 2016 | Volume: 98-B | Issue: 9 | Pages: 1180-1184

10.1302/0301-620x.98b9.37943 | PMID 27587517 Get It

Aims We compared the outcome of total hip arthroplasty (THA) in obese patients who previously underwent bariatric surgery and those who did not, in a matched cohort study. Patients and Methods There were 47 THAs in the bariatric group (42 patients), and 94 THAs in the comparison group (92 patients). The mean age of the patients was 57 years in both groups (24 to 79) and 57% of the patients in both groups were women. The mean time between bariatric surgery and THA was five years (four months to 12 years) in the bariatric group. The mean follow-up after THA was three years (2 to 9). Results The mean BMI improved from 49.7 kg/m2 (35 to 75) prior to bariatric surgery to 35.3 kg/m2 (21 to 49) at the time of THA (p < 0.001). Patients in the comparison group had an increased risk of re-operation (Hazard Ratio (HR) 3.2; 95% confidence intervals (CI) 1.3 to 9.5, p = 0.01) and revision (HR 5.4; 95% CI 1.5 to 34.5, p = 0.01) when compared with the bariatric group. Conclusion Patients had a dramatic improvement in BMI after bariatric surgery and those with prior bariatric surgery had a lower risk of re-operation and revision in the short- and mid-term after a subsequent THA. Larger prospective studies are required before it can be concluded that this extra surgery should be advised in these patients. Cite this article: Bone Joint J 2016;98-B:1180–4.
Clinical Spectrum of Medium‐Sized Vessel Vasculitis
Alıbaz-Öner, Fatma , Crowson, Cynthia S. , Makol, Ashima , Ytterberg, Steven R. , Matteson, Eric L. , Warrington, Kenneth J. , Koster, Matthew J. , Salvarani, Carlo , Warrington, Kenneth J , Makol, Ashima

Mayo Clinic

Arthritis Care & Research | August 26, 2016 | Volume: 69 | Issue: 6 | Pages: 884-891

10.1002/acr.23007 | PMID 27564269 Get It

ObjectivePolyarteritis nodosa (PAN) is a systemic necrotizing vasculitis of medium‐sized visceral vessels. However, cutaneous arteritis (CA) and gastrointestinal (GI) vasculitis are forms of single‐organ vasculitis having indistinguishable histopathologic findings from PAN. The aim of this study was to evaluate and compare the clinical characteristics, treatment, and outcomes of patients with systemic PAN, CA, and GI vasculitis.MethodsRetrospective cohorts were assembled, consisting of patients with PAN, CA, and GI vasculitis between 1980 and 2014. The demographics, clinical characteristics, treatment, and outcomes of patients were abstracted from medical records.ResultsWe included 48 patients with PAN, 41 patients with CA, and 19 patients with GI vasculitis. The disease of 1 patient evolved from CA to systemic PAN during the disease course. At diagnosis, 94% of patients with PAN, 93% of patients with CA, and 67% of patients with GI vasculitis were treated with glucocorticoids. Additional immunosuppressive agents were used in 67% of PAN, 37% of GI vasculitis, and 32% of CA cases. The 5‐year cumulative relapse rate was 45.2% in CA, and only 9.6% in PAN during a followup of approximately 6 years. No deaths were observed in the CA group. The survival rate at 10 years was 66% in the PAN group and 61% in the GI vasculitis group.ConclusionSystemic PAN, CA, and GI vasculitis take different clinical courses and therefore may be different diseases, rather than existing on a spectrum of the same disease. Progression of CA to systemic PAN is very rare. Relapse risk is low during followup in PAN. Patients with CA have a higher relapse rate than those with systemic PAN, possibly due to less use of immunosuppressive therapy in CA.
Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy
Ratain, Mark J. , Ratain, Mark, Ingle, James N. , Goetz, Matthew P.

Mayo Clinic

Journal of Clinical Oncology | August 23, 2016 | Volume: 34 | Issue: 32 | Pages: 3944-3945

10.1200/jco.2016.68.5214 | PMID 27551126 Get It

Low incidence of pneumocystis pneumonia utilizing PCR‐based diagnosis in patients with B‐cell lymphoma receiving rituximab‐containing combination chemotherapy
Barreto, Jason N. , Ice, Lauren L., Thompson, Carrie A. , Tosh, Pritish K. , Osmon, Douglas R. , Dierkhising, Ross , Plevak, Matthew F., Dierkhising, Ross A, Limper, Andrew H.

Mayo Clinic

American Journal of Hematology | August 22, 2016 | Volume: 91 | Issue: 11 | Pages: 1113-1117

10.1002/ajh.24499 | PMID 27472910 Get It

Recent literature has demonstrated concern over the risk of Pneumocystis jirovecii pneumonia (PJP) when administering rituximab with combination chemotherapy such as in R‐CHOP; however, the exact risk and potential need for prophylaxis is unknown. We sought to determine the incidence of PJP infection following R‐CHOP administration in patients with B‐cell lymphoma. Consecutive patients diagnosed with B‐cell lymphoma receiving R‐CHOP were evaluated from chemotherapy initiation until 180 days after the last administration. The primary outcome was cumulative incidence of PJP infection. Secondary endpoints included the association of rituximab, prednisone and subsequent chemotherapy with PJP infection risk. A total of 689 patients (53% male, median age 66 years) were included. Seventy‐three percent of patients completed at least 6 cycles of R‐CHOP treatment. Median rituximab and prednisone cumulative doses were 3950 mg and 5325 mg, respectively. Median daily prednisone dose through end of treatment was 45 mg (range 7.6 mg to 119 mg). The cumulative incidence of PJP was 1.51% (95% CI 0.57–2.43, at maximum follow‐up of 330 days), below 3.5%, the conventional threshold for prophylaxis. Univariate analysis did not detect a statistically significant association between PJP and rituximab, steroids, or receipt of additional chemotherapy in this patient population. Our results demonstrate a low occurrence of Pneumocystis pneumonia during R‐CHOP treatment of B‐cell lymphoma and argue against universal anti‐Pneumocystis prophylaxis in this setting. Further investigations should focus on targeted anti‐Pneumocystis prophylaxis for patients presenting with high‐risk baseline characteristics or when receiving rituximab‐inclusive intensive combination chemotherapy regimens as treatment for other aggressive lymphoma subtypes. Am. J. Hematol. 91:1113–1117, 2016. © 2016 Wiley Periodicals, Inc.
Ultrasonic bone aspirator (Sonopet) for meatal bone removal during retrosigmoid craniotomy for vestibular schwannoma
Modest, Mara C., Carlson, Matthew L. , Link, Michael J. , Driscoll, Colin L. W.

Mayo Clinic

The Laryngoscope | August 22, 2016 | Volume: 127 | Issue: 4 | Pages: 805-808

10.1002/lary.26219 | PMID 27546602 Get It

FTDP‐17 with Pick body‐like inclusions associated with a novel tau mutation, p.E372G
Tacik, Paweł , DeTure, Michael , Carlomagno, Yari , Lin, Wen‐Lang, Murray, Melissa E. , Josephs, Keith A. , Graff‐Radford, Neill R. , Parisi, Joseph E., Petrucelli, Leonard , Rademakers, Rosa , Isaacson, Richard , Heilman, Kenneth M. , Petersen, Ronald C. , Kouri, Naomi , DeTure, Michael A, Baker, Matthew C, Baker, Matthew , Boeve, Bradley F. , Wszołek, Zbigniew K. , Dickson, Dennis W. , Murray, Melissa E

Mayo Clinic

Brain Pathology | August 16, 2016 | Volume: 27 | Issue: 5 | Pages: 612-626

10.1111/bpa.12428 | PMID 27529406 Get It

AbstractMutations in microtubule‐associated protein tau gene (MAPT) cause frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP‐17). Here, we describe a patient with FTDP‐17 and a novel missense mutation in exon 13 of MAPT, p.E372G. We compare clinicopathologic features of this patient to two previously unreported patients with another exon 13 mutation, p.G389R. The patient with the p.E372G mutation was a 40‐year‐old man with behavioral variant frontotemporal dementia (bvFTD), who subsequently developed agrammatic speech and parkinsonism. One of the FTDP‐17 patients with p.G389R mutation presented at age 24 with agrammatic variant of primary progressive aphasia, and subsequently behavioral dysfunction. The other presented at age 53 with bvFTD, followed by agrammatic speech and corticobasal syndrome. Neuropathologic features of FTDP‐17 due to p.E372G were similar to those of p.G389R, including tau‐immunoreactive Pick body‐like neuronal inclusions and swollen, tapering thread‐like processes in white matter immunoreactive for 3‐repeat and 4‐repeat tau. Biochemical analysis of insoluble tau showed similar isoform compositions in p.E372G and p.G389R. Functional studies of the p.E372G mutation showed marked increase in tau filament formation and its reduced ability to promote microtubule assembly. Together these findings indicate that p.E372G is a pathogenic MAPT mutation that causes FTDP‐17 similar to p.G389R.
Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy
Tendulkar, Rahul D. , Agrawal, Shree , Gao, Tianming , Pisansky, Thomas M. , Michalski, Jeff M. , Hamstra, Daniel A. , Feng, Felix Y. , Liauw, Stanley L. , Abramowitz, Matthew C. , Pollack, Alan , Den, Robert B. , Stephans, Kevin L. , Zietman, Anthony L., Lee, W. Robert , Kattan, Michael W. , Stephenson, Andrew J. , Efstathiou, Jason A. , Koontz, Bridget F, Anscher, Mitchell S. , Moghanaki, Drew, Koontz, Bridget F. , Moghanaki, Drew M. , Den, Robert B , Liauw, Stanley L , Abramowitz, Matthew C , Kattan, Michael W

Mayo Clinic

Journal of Clinical Oncology | August 15, 2016 | Volume: 34 | Issue: 30 | Pages: 3648-3654

10.1200/jco.2016.67.9647 | PMID 27528718 Get It

Purpose We aimed to update a previously published, multi-institutional nomogram of outcomes for salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer, including patients treated in the contemporary era. Methods Individual data from node-negative patients with a detectable post-RP prostate-specific antigen (PSA) treated with SRT with or without concurrent androgen-deprivation therapy (ADT) were obtained from 10 academic institutions. Freedom from biochemical failure (FFBF) and distant metastases (DM) rates were estimated, and predictive nomograms were generated. Results Overall, 2,460 patients with a median follow-up of 5 years were included; 599 patients (24%) had a Gleason score (GS) ≤ 6, 1,387 (56%) had a GS of 7, 244 (10%) had a GS of 8, and 230 (9%) had a GS of 9 to 10. There were 1,370 patients (56%) with extraprostatic extension (EPE), 452 (18%) with seminal vesicle invasion (SVI), 1,434 (58%) with positive surgical margins, and 390 (16%) who received ADT (median, 6 months). The median pre-SRT PSA was 0.5 ng/mL (interquartile range, 0.3 to 1.1). The 5-yr FFBF rate was 56% overall, 71% for those with a pre-SRT PSA level of 0.01 to 0.2 ng/mL (n = 441), 63% for those with a PSA of 0.21 to 0.50 ng/mL (n = 822), 54% for those with a PSA of 0.51 to 1.0 ng/mL (n = 533), 43% for those with a PSA of 1.01 to 2.0 ng/mL (n = 341), and 37% for those with a PSA > 2.0 ng/mL (n = 323); P < .001. On multivariable analysis, pre-SRT PSA, GS, EPE, SVI, surgical margins, ADT use, and SRT dose were associated with FFBF. Pre-SRT PSA, GS, SVI, surgical margins, and ADT use were associated with DM, whereas EPE and SRT dose were not. The nomogram concordance indices were 0.68 (FFBF) and 0.74 (DM). Conclusion Early SRT at low PSA levels after RP is associated with improved FFBF and DM rates. Contemporary nomograms can estimate individual patient outcomes after SRT in the modern era.
Clinically significant intratumoral hemorrhage in patients with vestibular schwannoma
Carlson, Matthew L. , Tombers, Nicole M. , Driscoll, Colin L. W., Lane, John I. , Raghunathan, Aditya , Flemming, Kelly D. , Link, Michael J. , Van Gompel, Jamie J, Gompel, Jamie J. Van , Raghunathan, Aditya , Flemming, Kelly D

Mayo Clinic

The Laryngoscope | August 12, 2016 | Volume: 127 | Issue: 6 | Pages: 1420-1426

10.1002/lary.26193 | PMID 27515152 Get It

Legumain is activated in macrophages during pancreatitis
Edgington‐Mitchell, Laura E. , Wartmann, Thomas , Martinez, Alicia K. Fleming , Gocheva, Vasilena, Linden, Wouter A. van der, Withana, Nimali P., Aurelio, Luigi, Edgington-Mitchell, Daniel , Lieu, TinaMarie , Parker, Belinda S. , Graham, Bim , Reinheckel, Thomas , Furness, John B. , Joyce, Johanna A. , Störz, Peter , Halangk, Walter, Bogyo, Matthew , Bunnett, Nigel W. , Fleming, Alicia K, Verdoes, Martijn

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | August 11, 2016 | Volume: 311 | Issue: 3 | Pages: G548-G560

10.1152/ajpgi.00047.2016 | PMID 27514475 Get It

Pancreatitis is an inflammatory disease of the pancreas characterized by dysregulated activity of digestive enzymes, necrosis, immune infiltration, and pain. Repeated incidence of pancreatitis is an important risk factor for pancreatic cancer. Legumain, a lysosomal cysteine protease, has been linked to inflammatory diseases such as atherosclerosis, stroke, and cancer. Until now, legumain activation has not been studied during pancreatitis. We used a fluorescently quenched activity-based probe to assess legumain activation during caerulein-induced pancreatitis in mice. We detected activated legumain by ex vivo imaging, confocal microscopy, and gel electrophoresis. Compared with healthy controls, legumain activity in the pancreas of caerulein-treated mice was increased in a time-dependent manner. Legumain was localized to CD68+ macrophages and was not active in pancreatic acinar cells. Using a small-molecule inhibitor of legumain, we found that this protease is not essential for the initiation of pancreatitis. However, it may serve as a biomarker of disease, since patients with chronic pancreatitis show strongly increased legumain expression in macrophages. Moreover, the occurrence of legumain-expressing macrophages in regions of acinar-to-ductal metaplasia suggests that this protease may influence reprogramming events that lead to inflammation-induced pancreatic cancer.
Pancreatic Transection: An Unusual Youth Soccer Injury
McIlvain, Gary, Schaeffer, Matthew S., Hoxie, Samuel C., Giangarra, Charles E., Jones, Matthew L.

Mayo Clinic

Athletic Therapy Today | August 10, 2016 | Volume: 13 | Issue: 5 | Pages: 17-19

10.1123/att.13.5.17 Get It